Associate Professor Kevin Pfleger is a National Health and Medical Research Council (NHMRC) RD Wright Biomedical Research Fellow (Level 2) and Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research (formerly Western Australian Institute for Medical Research, WAIMR) and The University of Western Australia. Kevin was Chief Scientific Officer of Dimerix Bioscience from 2008 until Dimerix became a public company in June 2014.
He was awarded his MA and PhD from Cambridge and Edinburgh Universities respectively. A former National Health and Medical Research Council (NHMRC) Peter Doherty Research Fellow and Australian Research Council (ARC) Future Fellow, Kevin’s recent awards include: Western Australian Young Scientist of the Year 2009, NHMRC 10 of the Best Research Projects 2010, Australian Museum Eureka Prize for Emerging Leader in Science 2011, The Endocrine Society Early Investigators Award 2012, Western Australia Young Tall Poppy Science Award 2012, Endocrine Society of Australia Mid-Career Research Award 2014, NHMRC Research Excellence Award 2014 for the highest ranked fellowship in his category, and the Vice-Chancellor of The University of Western Australia’s Mid-Career Research Award 2015.
Kevin is one of the world’s foremost authorities on the use of bioluminescence resonance energy transfer (BRET) technologies to study G protein-coupled receptors. He has published the seminal review and protocol for BRET in Nature Methods and Nature Protocols respectively, and is co-inventor of the HIT technology assigned to Dimerix from The University of Western Australia.
Dr. Richardson was most recently a member of The Leadership Team and The Global Head of The Musculoskeletal Disease Therapeutic Area at The Novartis Institutes for Biomedical Research having previously held several other senior positions during a 42 year career in the Pharmaceutical Industry. Those positions included Deputy Head of Drug Safety, Head of Pathology and Experimental Toxicology, Head of Immunology, Inflammation and Respiratory Research as well as Senior Project Manager for the worldwide development of new therapies for Metabolic, Cardiovascular and Respiratory Diseases for Sandoz Pharma. Subsequently Dr. Richardson was appointed Head of Preclinical Research in Switzerland and UK and played a key role in the merger of the Sandoz and Ciba Research organisations that ultimately resulted in creation of The Novartis Institutes for Biomedical Research.
Research conducted in Dr. Richardson’s laboratories has led to the discovery, development and introduction of several new therapies. He has published more than 60 original peer reviewed research papers and contributed many book chapters in the fields of pathophysiology, endocrinology and receptor pharmacology.
David has extensive experience in research, financial analysis, funds management and business strategy.
His career includes 15 years in the Australian stockbroking industry and 10 years in the funds management sector as well as experience in company management and business strategy. He is an experienced company director, having been Chairman, executive director and non executive director of various ASX listed companies. Most recently, David was Chairman of Onterran Ltd until April 2015.
David has strong business management expertise incorporating company restructuring, strategy development, people management, corporate culture and organisational structure.
David is currently the managing director of Village National Holdings Limited.
Sonia has worked within Swiss Stock Exchange listed companies Hoffman la Roche and Addex Therapeutics, where she has held leadership and executive positions across various disciplines in drug discovery, pre-clinical development and translational science and has interacted with regulatory authorities, investors and public funding institutions. Sonia has held various corporate responsibilities such as outsourcing and out-licensing, and she has promoted academic collaborations and supported R&D collaborations with external partners.
Sonia is an accomplished R&D professional with 20 years international experience in large and small pharmaceutical companies. She has broad knowledge of small molecule drug design, optimisation and early clinical development, with expertise which encompasses multiple therapeutic areas.
Sonia is co-author of more than 40 scientific papers and several patents. Sonia holds a Masters degree and a PhD in industrial chemistry from Milan University (IT).
James is a Founder and Investment Director of Yuuwa Capital LP, a venture capital firm based in Western Australia and was the CEO of Dimerix between 2007 and 2009. Prior to establishing Yuuwa Capital and managing Dimerix, James was Managing Director of two medical device companies, ASX-listed Resonance Health Ltd and Argus Biomedical Pty Ltd, both of which took their products to market under his guidance. He also co-founded and is a former CSO and Director of iCeutica, Inc., a clinical stage nano drug reformulation company that was acquired in 2011. James is a Director of Yuuwa investee companies Adalta Pty Ltd, Eridan Technology Pty Ltd, Nexgen Plants Pty Ltd and PolyActiva Pty Ltd. He is also a Director of Linear Clinical Research Ltd, a specialist early phase clinical trial unit and a member of the “Panel of Experts” for the University of Western Australia’s Pathfinder Fund. He completed his undergraduate degree in Biochemistry at the University of Aberdeen, PhD at Melbourne University and MBA at the University of Western Australia.
Hugh is an accomplished pharmaceutical and biotechnology executive with 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. He has demonstrated commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Hugh has an enviable track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products.
Hugh’s most recent role was the Chief Executive Officer of Hatchtech Pty Ltd, which he helped secure he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as Director of Business Development at Acrux Limited, Hugh was a key member of the team that secured at the time the single largest product licensing deal by an Australian biotech company, when Acrux licensed its testosterone product, Axiron™, to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties.
Ian is a fellow chartered accountant and experienced chartered secretary who acts as non-executive director and company secretary to ASX listed companies, trustee corporations, charitable trusts and private organisations. Prior to commencing his own practice, Ian had in excess of 20 years professional accounting experience working for large chartered accounting firms together with commercial experience in Australia, UK and Canada.
As an experienced finance and corporate governance professional, Ian brings a wealth of experience to boards contributing to financial management, corporate governance, capital raising strategies and transaction and due diligence capabilities drawn from exposure to a variety of industries.
Ian is a facilitator with the AICD and presents the finance units for the Company Director Course.
Kathy has more than 20 years experience within the Australian Biotech Industry, focussing on commercialisation of company IP assets.
Previously, Kathy has worked within ASX listed companies AMRAD Biotech, Cytopia Research Pty Ltd, and Phosphagenics Limited, in a wide variety of functions such as product development, clinical development, document control and IP strategy and management. Kathy has held various corporate responsibilities such as management of human resources, scheme of arrangement merger due diligence and R&D tax incentive applications. Kathy also spent 9 years in private practice as a patent and trade mark attorney at Watermark, gaining a wealth of experience in the legal framework underscoring commercialisation of technologies.
Kathy holds a Master of Science from Manchester University (UK), a Certificate in Governance (Practice) from the Governance Institute of Australia, and is a Registered Patent and Trade Mark Attorney in Australia and Fellow of the Institute of Patent and Trade Mark Attorneys.